Charles River Raises 2026 Outlook as Q3 Organic Growth Reaches 4.7%

Charles River Laboratories International raised its 2026 revenue and earnings guidance after third-quarter organic growth and adjusted profit exceeded its prior outlook, supported by stronger Discovery and Safety Assessment activity and a lower tax rate.

The contract research company said third-quarter organic revenue grew 4.7%, above its previous forecast of 1% to 3% and following 0.1% growth in the second quarter. Reported revenue declined 2.2% year over year to $982.7 million, reflecting the effect of divestitures and other adjustments included in the company’s organic growth calculation.

Non-GAAP diluted earnings rose 27.2% to $3.09 per share, exceeding Charles River’s prior range of $2.90 to $3.00. GAAP diluted earnings increased to $6.86 from $1.10, while GAAP operating margin expanded 730 basis points to 20.6%. Non-GAAP operating margin rose 330 basis points to 23.0%, helped by higher study volumes and lower non-human primate sourcing costs in the Discovery and Safety Assessment segment, benefits from divestitures and lower unallocated corporate costs.

Safety assessment demand supports growth

Discovery and Safety Assessment, Charles River’s largest segment, generated revenue of $596.3 million, down 0.7% on a reported basis but up 5.9% organically. Growth was driven by higher volumes for regulated safety assessment services, including strong demand for non-human primate-related studies and bioanalysis.

The segment’s non-GAAP operating margin increased 140 basis points to 26.8%, primarily reflecting operating leverage from increased study volumes and lower costs for non-human primates sourced from Cambodia. Management expects the margin to improve sequentially again in the fourth quarter as those sourcing benefits continue and fringe-benefit costs decline.

Demand indicators remained positive. Quarterly net bookings reached $652 million, producing a net book-to-bill ratio of 1.09 times, compared with 0.82 times a year earlier. Backlog increased to $2.03 billion from $1.80 billion, while the trailing 12-month net book-to-bill ratio averaged about 1.1 times. Charles River said this level supports its long-term target for 5% to 7% annual organic revenue growth in the segment from 2027 through 2030.

The dollar value of Discovery and Safety Assessment proposals increased year over year for a fifth consecutive quarter, with both global biopharmaceutical companies and small and midsized biotechnology clients contributing. Charles River also recently expanded a safety assessment relationship with a top-10 biopharmaceutical company, with incremental work expected to transition to the company over the next 12 to 18 months.

Charles River has begun modestly reducing discounting in recent proposals while maintaining its capture rate. The company cautioned that the process is at an early stage and has not yet benefited revenue. Even if current trends continue, management does not expect a pricing contribution before at least the second half of 2027 because newly booked studies must move through the backlog.

Manufacturing margins rise after divestiture

Manufacturing Solutions revenue fell 6.2% on a reported basis to $178.9 million but increased 7.4% organically. Microbial Solutions recorded similar organic growth, supported by demand for endotoxin-testing cartridges and reagents across its three major geographic regions. The company placed nine automated Endosafe NEXUS instruments during the quarter, which it expects to generate additional cartridge use over time.

Biologics Testing delivered high-single-digit organic growth, led by demand for in vitro biosafety and analytical testing services. The business also passed the anniversary of a client-specific issue that had weighed on results since mid-2025.

Manufacturing’s non-GAAP operating margin climbed to 38.6% from 26.7%, reflecting the full-quarter benefit from the CDMO divestiture and operating leverage from revenue growth. Management expects the margin to approach 40% in the fourth quarter.

Research Models and Services remained the weakest segment. Revenue declined 2.8% to $207.5 million and fell 0.6% organically. Lower small-model sales in North America were largely offset by strong demand in China, while third-party non-human primate revenue declined because of shipment timing. Insourcing Solutions benefited from new government contract awards, but the CRADL business was stable and had not returned to growth.

The segment’s non-GAAP operating margin decreased 60 basis points to 24.4% because of an unfavorable geographic and product mix, including lower non-human primate revenue. Charles River said uncertainty surrounding government funding continued to pressure North American small-model volumes. Academic and government customers account for nearly 40% of annual segment revenue, limiting the recovery in its growth rate.

2026 guidance raised

Charles River now expects 2026 reported revenue to decline 1.5% to 2.0%, compared with its previous forecast for a 2.5% to 3.5% decrease. Organic revenue is expected to grow at least 1.5%, up from the prior range of zero to 1.0%.

The company raised its full-year non-GAAP EPS forecast to $11.35 to $11.55 from $11.15 to $11.45, citing third-quarter outperformance, particularly in Discovery and Safety Assessment, and a lower tax rate. GAAP EPS is now projected at $8.15 to $8.35, compared with $3.05 to $3.35 previously. The increase mainly reflects a $245.6 million noncash benefit associated with the release of acquired tax reserves following newly enacted tax legislation and the completion of tax requirements in a foreign jurisdiction.

For the fourth quarter, Charles River expects mid-single-digit organic growth in Discovery and Safety Assessment and high-single-digit growth in Manufacturing. Research Models and Services is expected to post a modestly lower organic growth rate than in the third quarter. The company also projects sequential non-GAAP operating-margin improvement of about 150 basis points and non-GAAP EPS growth of approximately 30% to 40% year over year.

Full-year free cash flow guidance remains $400 million to $420 million, and the capital expenditure forecast is unchanged at approximately $200 million. Third-quarter free cash flow increased to $207.3 million from $178.2 million, mainly because of working-capital timing.

Risks identified in the presentation include changes in biopharmaceutical research spending and outsourcing, government funding uncertainty, the availability and cost of non-human primates, regulation of preclinical testing, foreign-exchange and interest-rate movements, and the company’s ability to convert backlog into revenue. Charles River also noted that actual results could differ from its outlook because of broader economic conditions, client demand, legal and regulatory developments, and execution of its restructuring, efficiency and strategic initiatives.